Fosaprepitant API
Pharmaceutical Oncology
Pharmaceutical API

Fosaprepitant

High-purity pharmaceutical grade Fosaprepitant API manufactured to meet stringent USP/EP specifications for antiemetic formulations. Our pharmaceutical grade API delivers exceptional purity and consistency for critical drug manufacturing applications.

  • USP/EP Grade Quality Standards
  • High Purity ≥99.0% (HPLC)
  • Comprehensive Analytical Documentation
  • Regulatory Compliance Support
  • cGMP Manufacturing Standards
  • Pharmaceutical Grade Packaging

Technical Specifications

Chemical Formula: C23H22F7N4O3P
CAS Number: 172673-20-0
Molecular Weight: 614.40 g/mol
Purity (HPLC): ≥99.0% (pharmaceutical grade)
Physical State: White to off-white powder
Water Content (Karl Fischer): ≤5.0%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤1.0% total impurities
Storage Conditions: Store in cool, dry place (15-25°C)
Packaging Options: 100g, 500g pharmaceutical containers

Applications

Antiemetic Drug Manufacturing
Cancer Supportive Care Formulations
NK1 Receptor Antagonist Products
API Synthesis & Development
Oncology Research Applications
Pharmaceutical Research
Drug Product Manufacturing
Quality Control Testing
Regulatory Compliance
Clinical Trial Materials
Bioanalytical Method Development
Reference Standard Applications

Industry-Specific Grades

DRAVYOM offers specialized Fosaprepitant grades tailored for specific pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse antiemetic and cancer supportive care drug manufacturing applications.

USP Grade (Pharmaceutical)
Purity: ≥99.0% (HPLC) Water Content: ≤5.0% Heavy Metals: ≤10 ppm Application: Pharmaceutical formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% (pharmaceutical) Related Substances: ≤1.0% Residue on Ignition: ≤0.1% Application: European market compliance
Research Grade
Purity: ≥98.0% (analytical) Water Content: ≤6.0% Particle Size: Controlled Application: R&D, method development
GMP Grade
Purity: ≥99.5% (pharmaceutical) Endotoxins: ≤2.5 EU/mg Microbial Limits: Compliant Application: Antiemetic formulations

Quality Standards

DRAVYOM's pharmaceutical grade Fosaprepitant is manufactured under stringent cGMP protocols, meeting international pharmaceutical standards including USP, EP, and ICH guidelines. Our pharmaceutical-grade production ensures consistent quality and regulatory compliance.

cGMP Certified Manufacturing
USP/EP Grade Specifications
≥99.0% Pharmaceutical Purity
Advanced Analytical Testing
Ultra-Low Impurities
Batch-to-Batch Consistency
Traceable Certificate of Analysis
Temperature-Controlled Logistics

Advanced Chemical Properties & Performance

Pharmaceutical grade Fosaprepitant exhibits precise chemical properties essential for antiemetic formulations. Its ultra-pure composition and exact molecular structure ensure reliable therapeutic performance in demanding pharmaceutical applications.

Pharmaceutical Properties
Molecular Weight: 614.46 g/mol
Melting Point: 148-152°C
Solubility (Water): 0.55 mg/mL at 25°C
LogP (Octanol/Water): 3.2
Physical Properties
Appearance: White to off-white powder
Crystalline Form: Crystalline solid
Bulk Density: 0.40-0.50 g/mL
Hygroscopicity: Non-hygroscopic
Pharmaceutical Performance
Bioavailability: 100% IV administration
Half-life: 2.3 hours
Protein Binding: 95%
Metabolism: Hepatic (CYP3A4)
Purity Specifications
Assay: ≥99.0% (HPLC)
Related Substances: ≤0.15% total
Residual Solvents: ICH Q3C compliant
Heavy Metals: ≤10 ppm
Stability Properties
Shelf Life: 3 years (unopened)
Storage Temperature: 15-30°C
Light Sensitivity: Protect from light
Moisture Sensitivity: Store in dry conditions

Performance Characteristics

Detailed performance metrics demonstrate pharmaceutical grade Fosaprepitant superiority in antiemetic applications with exceptional stability, bioavailability, and reproducibility across diverse pharmaceutical formulations.

Formulation Performance

Compatibility: Excellent with standard excipients

Consistent injection preparation
Therapeutic Efficacy

Bioequivalence: 95-105% reference standard

Proven therapeutic equivalence
Dissolution Profile

Release: Rapid IV dissolution

Optimal pharmaceutical performance
Thermal Stability

Stability: <0.1% degradation/year at 25°C

Excellent long-term stability
Batch Consistency

Variation: ±0.3% between production batches

Exceptional pharmaceutical uniformity
Shelf Stability

3 years under controlled storage conditions

Extended pharmaceutical grade integrity

Safety Information

Pharmaceutical grade compound requiring proper handling procedures. Use appropriate personal protective equipment including gloves, safety goggles, and protective clothing. Ensure adequate ventilation and follow established pharmaceutical handling protocols.

Handle with Care
Eye Protection Required
Avoid Inhalation

Storage & Handling

Store in original pharmaceutical containers in a cool, dry, well-ventilated area away from incompatible materials. Keep containers tightly closed and protect from light and moisture. Follow cGMP storage requirements for pharmaceutical materials.

Controlled temperature (15-30°C)
Protect from moisture
Original pharmaceutical packaging
Protect from direct light

Chemical Mechanisms & Reaction Pathways

Fosaprepitant functions as a prodrug of aprepitant, exhibiting NK1 receptor antagonism after conversion, providing effective prevention of chemotherapy-induced nausea and vomiting through selective neurokinin-1 receptor blockade.

Prodrug Activation

Conversion to active aprepitant after administration

Enhanced bioavailability and dosing flexibility
NK1 Receptor Antagonism

Selective neurokinin-1 receptor competitive inhibition

Blocks substance P-mediated emesis
Central Antiemetic Action

Crosses blood-brain barrier for CNS activity

Prevents delayed-phase nausea
Long Duration

Extended antiemetic effect up to 120 hours

Sustained chemotherapy protection

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures antiemetic pharmaceutical manufacturing access with complete documentation packages supporting international standards and chemotherapy supportive care development.

USP Standards

United States Pharmacopeia antiemetic drug specifications

EP Monograph

European Pharmacopoeia specifications for NK1 receptor antagonists

Antiemetic GMP

Specialized GMP for antiemetic drug manufacturing

ICH Guidelines

International antiemetic drug development regulatory compliance

Antiemetic DMF

Drug Master File for antiemetic applications

Safety Documentation

Comprehensive antiemetic safety and pharmacovigilance documentation

Technical Support & Value-Added Services

DRAVYOM's antiemetic pharmaceutical team provides comprehensive formulation support, stability testing, and regulatory services for Fosaprepitant chemotherapy supportive care applications.

Antiemetic Formulation
  • NK1 receptor antagonist formulation optimization
  • Injectable and oral development
  • Bioavailability enhancement
  • Custom antiemetic development
Analytical Services
  • API purity and potency analysis
  • Antiemetic impurity profiling
  • Stability testing protocols
  • Method validation support
Regulatory Support
  • Antiemetic regulatory filing
  • DMF preparation and maintenance
  • International compliance guidance
  • Antiemetic pharmacovigilance
Supply Solutions
  • Antiemetic pharmaceutical supply chain
  • Custom packaging solutions
  • Global distribution network
  • Emergency antiemetic supply

Environmental Impact & Sustainability

Our Fosaprepitant production emphasizes environmental responsibility through sustainable pharmaceutical manufacturing practices, waste minimization, and comprehensive environmental impact management.

Green Chemistry

Environmentally friendly synthesis and processing methods

Water Conservation

Advanced water treatment and recycling systems

Clean Production

Energy-efficient pharmaceutical manufacturing processes

Waste Reduction

Comprehensive pharmaceutical waste management protocols

ISO 14001

Environmental management system certified production

Sustainable Sourcing

Responsible procurement of pharmaceutical raw materials

Manufacturing Excellence & Quality Control

DRAVYOM's pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent Fosaprepitant quality and antiemetic therapeutic performance.

Pharmaceutical GMP

Advanced manufacturing in controlled clean-room environment

Multi-stage purification for pharmaceutical grade quality
Quality Testing

Comprehensive testing including assay, impurities, and stability

HPLC verification and antiemetic analysis
Quality Systems

ISO 9001:2015 quality management with pharmaceutical compliance

Continuous improvement and pharmaceutical validation
Pharmaceutical Packaging

Pharmaceutical-grade containers with stability protection

Stability protection and contamination prevention

Market Applications & Performance Data

Comprehensive antiemetic data demonstrating Fosaprepitant effectiveness in chemotherapy-induced nausea and vomiting with quantified performance metrics and clinical validation data.

Antiemetic Formulations
Bioavailability: Rapid conversion to aprepitant Stability: 3-year shelf life validated Compatibility: Excellent with injection vehicles
Therapeutic Applications
CINV: Proven chemotherapy-induced nausea prevention PONV: Effective post-operative nausea control Safety: Well-tolerated NK1 antagonist
Manufacturing Performance
Yield: 90% pharmaceutical grade recovery Purity: >98.0% pharmaceutical specification Consistency: 99.2% batch-to-batch reproducibility

DRAVYOM Competitive Advantages

Antiemetic Excellence

Superior pharmaceutical grade with proven NK1 receptor selectivity and regulatory compliance

Reliable Supply

Guaranteed antiemetic supply with strategic inventory management and specialized production

Supportive Care Expertise

Dedicated supportive care development team with specialized antiemetic formulation support

Regulatory Compliance

Complete antiemetic documentation with DMF support and international compliance

Global Standards

International pharmaceutical compliance with USP, EP, and ICH guidelines

Partnership Approach

Collaborative antiemetic relationships with specialized development services